Literature DB >> 27501218

Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells.

David J Agorku1, Stefan Tomiuk2, Kerstin Klingner3, Stefan Wild2, Silvia Rüberg2, Lisa Zatrieb2, Andreas Bosio2, Julia Schueler3, Olaf Hardt2.   

Abstract

The use of in vitro cell line models for cancer research has been a useful tool. However, it has been shown that these models fail to reliably mimic patient tumors in different assays(1). Human tumor xenografts represent the gold standard with respect to tumor biology, drug discovery, and metastasis research (2-4). Tumor xenografts can be derived from different types of material like tumor cell lines, tumor tissue from primary patient tumors(4) or serially transplanted tumors. When propagated in vivo, xenografted tissue is infiltrated and vascularized by cells of mouse origin. Multiple factors such as the tumor entity, the origin of xenografted material, growth rate and region of transplantation influence the composition and the amount of mouse cells present in tumor xenografts. However, even when these factors are kept constant, the degree of mouse cell contamination is highly variable. Contaminating mouse cells significantly impair downstream analyses of human tumor xenografts. As mouse fibroblasts show high plating efficacies and proliferation rates, they tend to overgrow cultures of human tumor cells, especially slowly proliferating subpopulations. Mouse cell derived DNA, mRNA, and protein components can bias downstream gene expression analysis, next-generation sequencing, as well as proteome analysis (5). To overcome these limitations, we have developed a fast and easy method to isolate untouched human tumor cells from xenografted tumor tissue. This procedure is based on the comprehensive depletion of cells of mouse origin by combining automated tissue dissociation with the benchtop tissue dissociator and magnetic cell sorting. Here, we demonstrate that human target cells can be can be obtained with purities higher than 96% within less than 20 min independent of the tumor type.

Entities:  

Mesh:

Year:  2016        PMID: 27501218      PMCID: PMC5091706          DOI: 10.3791/54259

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  18 in total

1.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.

Authors:  Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm
Journal:  Nat Med       Date:  2011-10-23       Impact factor: 53.440

2.  Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro.

Authors:  B E Reubinoff; M F Pera; C Y Fong; A Trounson; A Bongso
Journal:  Nat Biotechnol       Date:  2000-04       Impact factor: 54.908

Review 3.  New models for cancer research: human cancer stem cell xenografts.

Authors:  Marta Baiocchi; Mauro Biffoni; Lucia Ricci-Vitiani; Emanuela Pilozzi; Ruggero De Maria
Journal:  Curr Opin Pharmacol       Date:  2010-06-17       Impact factor: 5.547

4.  Using VarScan 2 for Germline Variant Calling and Somatic Mutation Detection.

Authors:  Daniel C Koboldt; David E Larson; Richard K Wilson
Journal:  Curr Protoc Bioinformatics       Date:  2013-12

5.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.

Authors:  Vincent C Daniel; Luigi Marchionni; Jared S Hierman; Jonathan T Rhodes; Wendy L Devereux; Charles M Rudin; Rex Yung; Giovanni Parmigiani; Marion Dorsch; Craig D Peacock; D Neil Watkins
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

Authors:  E Boven; B Winograd; D P Berger; M P Dumont; B J Braakhuis; O Fodstad; S Langdon; H H Fiebig
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

Review 7.  Patient-derived tumor xenografts: transforming clinical samples into mouse models.

Authors:  Despina Siolas; Gregory J Hannon
Journal:  Cancer Res       Date:  2013-06-03       Impact factor: 12.701

Review 8.  Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Authors:  B Rubio-Viqueira; M Hidalgo
Journal:  Clin Pharmacol Ther       Date:  2008-11-12       Impact factor: 6.875

9.  Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours.

Authors:  Stephen Q Wong; Jason Li; Renato Salemi; Karen E Sheppard; Hongdo Do; Richard W Tothill; Grant A McArthur; Alexander Dobrovic
Journal:  Sci Rep       Date:  2013-12-13       Impact factor: 4.379

10.  Trimmomatic: a flexible trimmer for Illumina sequence data.

Authors:  Anthony M Bolger; Marc Lohse; Bjoern Usadel
Journal:  Bioinformatics       Date:  2014-04-01       Impact factor: 6.937

View more
  3 in total

1.  Impact of the Injection Site on Growth Characteristics, Phenotype and Sensitivity towards Cytarabine of Twenty Acute Leukaemia Patient-Derived Xenograft Models.

Authors:  Julia Schueler; Gabriele Greve; Dorothée Lenhard; Milena Pantic; Anna Edinger; Eva Oswald; Michael Lübbert
Journal:  Cancers (Basel)       Date:  2020-05-25       Impact factor: 6.639

2.  Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion.

Authors:  Takumi Shiraishi; Shogo Inui; Yuta Inoue; Yumiko Saito; Hideto Taga; Masatomo Kaneko; Keisuke Tsuji; Saya Ueda; Takashi Ueda; Toru Matsugasumi; Hidefumi Taniguchi; Akihisa Ueno; Takeshi Yamada; Yasuhiro Yamada; Tsuyoshi Iwata; Atsuko Fujihara; Fumiya Hongo; Osamu Ukimura
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

3.  Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research.

Authors:  Magdalena Cybula; Lin Wang; Luyao Wang; Ana Luiza Drumond-Bock; Katherine M Moxley; Doris M Benbrook; Camille Gunderson-Jackson; Maria J Ruiz-Echevarria; Resham Bhattacharya; Priyabrata Mukherjee; Magdalena Bieniasz
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.